Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05186805 · ClinicalTrials.gov registry record · Phase 2
Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Organon and.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 10
- Study locations
NCT05186805: Completed Phase 2 study of Atopic Dermatitis, sponsored by Organon and.
NCT05186805 is a Phase 2 study of Atopic Dermatitis that has completed, run by Organon and. The registered enrollment target is 36 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (94% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05186805, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Organon and.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in pediatric subjects with atopic dermatitis
Primary Outcome
Number of Participants that Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs).
Conditions Studied
Interventions
- DRUG Tapinarof cream, 1%
Study Locations (10)
Florida
- Dermavant Investigative Site - Coral Gables
- Dermavant Investigative Site - Hialeah
- Dermavant Investigative Site - Miami Lakes
Texas
- Dermavant Investigative Site - Houston
- Dermavant Investigative Site - San Antonio
California
- Dermavant Investigative Site - Thousand Oaks
Colorado
- Dermavant Investigative Site - Centennial
Illinois
- Dermavant Investigative Site - Chicago
South Carolina
- Dermavant Investigative Site - Summerville
Alberta
- Dermavant Investigative Site - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2022-08-24 |
| Phase | Phase 2 |
What the finished NCT05186805 record still lists
NCT05186805 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Tapinarof cream, 1% is the first listed.
NCT05186805 lists 10 locations in 7 states (Florida, Texas, California).
Frequently Asked Questions
What is clinical trial NCT05186805 about?
NCT05186805 is a clinical study titled "Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis". This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in pediatric subjects with atopic dermatitis
What is the current status of trial NCT05186805?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2021-11-15. Estimated completion is 2022-08-24.
What conditions does trial NCT05186805 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT05186805?
The interventions under investigation include: Tapinarof cream, 1% (DRUG).
Who is sponsoring clinical trial NCT05186805?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05186805 being conducted?
This trial has 10 study locations across California, Colorado, Florida, Illinois, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05186805's enrollment target sits among peer trials
36 116th of 150 higher than 35 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI